- Home
- OS vs NUVL Comparison
OS vs NUVL Comparison
Compare OS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OS
- NUVL
- Stock Information
- Founded
- OS 2012
- NUVL 2017
- Country
- OS United States
- NUVL United States
- Employees
- OS N/A
- NUVL N/A
- Industry
- OS
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OS
- NUVL Health Care
- Exchange
- OS NYSE
- NUVL Nasdaq
- Market Cap
- OS 7.1B
- NUVL 6.7B
- IPO Year
- OS 2024
- NUVL 2021
- Fundamental
- Price
- OS $29.66
- NUVL $84.22
- Analyst Decision
- OS Strong Buy
- NUVL Strong Buy
- Analyst Count
- OS 19
- NUVL 10
- Target Price
- OS $35.67
- NUVL $112.60
- AVG Volume (30 Days)
- OS 1.1M
- NUVL 429.4K
- Earning Date
- OS 02-15-2025
- NUVL 11-12-2024
- Dividend Yield
- OS N/A
- NUVL N/A
- EPS Growth
- OS N/A
- NUVL N/A
- EPS
- OS N/A
- NUVL N/A
- Revenue
- OS $459,526,000.00
- NUVL N/A
- Revenue This Year
- OS $33.26
- NUVL N/A
- Revenue Next Year
- OS $20.42
- NUVL N/A
- P/E Ratio
- OS N/A
- NUVL N/A
- Revenue Growth
- OS 64.51
- NUVL N/A
- 52 Week Low
- OS $24.50
- NUVL $61.80
- 52 Week High
- OS $35.39
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OS N/A
- NUVL 32.94
- Support Level
- OS N/A
- NUVL $81.37
- Resistance Level
- OS N/A
- NUVL $89.31
- Average True Range (ATR)
- OS 0.00
- NUVL 3.37
- MACD
- OS 0.00
- NUVL -0.95
- Stochastic Oscillator
- OS 0.00
- NUVL 18.24
About OS ONESTREAM INC
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.